Educational Activities Archives

Lab testing in the assessment of substance use disorders may involve many different substrates, though urine drug testing (UDT) dominates clinical practice. This course is meant to provide a short guide to effective use of lab testing in the treatment of the patient with a substance use disorder, which, to a surprising degree, is often misused or misunderstood. The course describes the clinical role of lab testing to guide treatment and not to be punitive. To properly use and interpret UDT, it reviews common false positives and false negatives that might occur in the immunologic-based first step in UDT. To understand confirmatory gas chromatography/mass spectrometry, it goes on to describe the metabolism of common opioids and benzodiazepines, because the detected substance is often just a downstream metabolite of several possible parent compounds to which the patient was exposed. The course concludes with a discussion of the difference between UDT for clinical purposes versus forensic ones.

Overdose is the leading cause of accidental injury death in the United States, surpassing motor vehicle crashes, claiming more than 100,000 American lives annually in 2022 and 2023. Promisingly, overdose deaths dropped to 80,341 in 2024. Fentanyl, a synthetic opioid sold as heroin and counterfeit prescription opioids, and commonly contaminating cocaine and methamphetamine, is driving surges in overdose deaths in most communities. This course will introduce tools to combat overdose, which include overdose education and naloxone distribution, compassionate overdose response, drug checking, engagement and treatment, and safety planning.

Stimulant use, including cocaine, methamphetamine and prescription stimulants, continues to be a growing and urgent public health concern. According to the 2024 National Survey on Drug Use and Health, 9 million people in the U.S. had used stimulants not as prescribed in the past year. Though opioids are often the focus of overdose conversations, stimulant-related overdose deaths reached an estimated 51,630 in 2024, while 59% of all overdoses from January 2021 through June 2024 involved a stimulant (Centers for Disease Control and Prevention, 2025). These trends underscore the critical need for effective treatment and engagement strategies. Several evidence-based behavioral therapies exist to help providers treat stimulant use disorder. This webinar will outline the clinical and administrative approaches to assess, treat and support people experiencing stimulant use disorder.

This activity focuses on the assessment, mitigation and management of risk when prescribing opioids for analgesia. Learners are introduced to the concept of universal precautions and their role in opioid therapy, as well as to practical monitoring and documentation strategies. The fundamental principles of urine drug testing and interpretation are also reviewed, as is the differential diagnosis of opioid misuse. Special attention is given to overdose prevention, naloxone co-prescribing, and how to recognize and respond to an emerging opioid use disorder when prescribing chronic opioid therapy for pain.

Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.

Controlled substances, including opioids, benzodiazepines, and medical cannabis, are commonly prescribed for the treatment of chronic pain. Urine drug screens (UDS) are often used in clinical practice to test for the presence of prescribed drugs to monitor compliance. Understanding how to appropriately interpret the results of urine drug screening is critical to providing effective patient care and maintaining patient trust. Pharmacists in various practice settings can play important roles in urine drug screenings.